Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Open accessThe DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Proteins with expanded polyglutamine repeats cause Huntington's disease and other neurodegenerative diseases. Transcriptional dysregulation and loss of function of transcriptional co-activator proteins have been implicated in the pathogenesis of these diseases. Huntington's disease is caused by expansion of a repeated sequence of the amino acid glutamine in the abnormal protein huntingtin (Htt). Here we show that the polyglutamine-containing domain of Htt, Htt exon 1 protein (Httex1p), directly binds the acetyltransferase domains of two distinct proteins: CREB-binding protein (CBP) and p300/CBP-associated factor (P/CAF). In cell-free assays, Httex1p also inhibits the acetyltransferase activity of at least three enzymes: p300, P/CAF and CBP. Expression of Httex1p in cultured cells reduces the level of the acetylated histones H3 and H4, and this reduction can be reversed by administering inhibitors of histone deacetylase (HDAC). In vivo, HDAC inhibitors arrest ongoing progressive neuronal degeneration induced by polyglutamine repeat expansion, and they reduce lethality in two Drosophila models of polyglutamine disease. These findings raise the possibility that therapy with HDAC inhibitors may slow or prevent the progressive neurodegeneration seen in Huntington's disease and other polyglutamine-repeat diseases, even after the onset of symptoms.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The progression of neurodegeneration is slowed by treatment with deacetylase inhibitors, further emphasizing the impor- tance of a controlled balance of protein acetylation and deacetylation in cellular functions in diverse tissues (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
In the citing paper
“A recent report showed that neurodegeneration triggered by expression of the polyglutamine-containing protein Httex1p involves inhibition of CBP/p300- and PCAF-AT activities (73).”
From Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 (2002) · cites this paper as [73]
Citations
Cites
Targeted gene expression as a means of altering cell fates and generating dominant phenotypes
Brand, A. H., & Perrimon, N. (1993) · Development · doi:10.1242/dev.118.2.401 · Cited by 9,612
Mangiarini, L., Sathasivam, K., Seller, M., Cozens, B., Harper, A., Hetherington, C., Lawton, M., Trottier, Y., Lehrach, H., Davies, S. W., et al. (1996) · Cell · doi:10.1016/s0092-8674(00)81369-0 · Cited by 3,073
CBP/p300 in cell growth, transformation, and development
Goodman, R. H., & Smolik, S. (2000) · Genes & Development · doi:10.1101/gad.14.13.1553 · Cited by 1,778
Saudou, F., Finkbeiner, S., Devys, D., & Greenberg, M. E. (1998) · Cell · doi:10.1016/s0092-8674(00)81782-1 · Cited by 1,595 · cited 1×
“We found that even normal repeat Htt can bind to and inhibit acetyltransferase activity ( Figs 1 and 2 ), so why is pathology associated with only expanded repeat Htt? Mutant Htt can be proteolytically processed; the pathogenic fragment localizes to the nucleus, where it is capable of inhibiting acetyltransferase acti…”
BackgroundA p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
Yang, X.-J., Ogryzko, V. V., Nishikawa, J.-I., Howard, B. H., & Nakatani, Y. (1996) · Nature · doi:10.1038/382319a0 · Cited by 1,479 · cited 1×
“, pGST–P/CAF-AT domain (encoding amino acids 87–768), and pcDNA3 containing the cDNA for P/CA”
MethodGlutamine Repeats and Neurodegeneration
Zoghbi, H. Y., & Orr, H. T. (2000) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.23.1.217 · Cited by 1,309 · cited 1×
“The aetiology of several other neurodegenerative diseases, including spinocerebellar ataxia I and Kennedy's disease, also involves expansion of a polyglutamine repea”
BackgroundHistone Deacetylase Inhibitors: Inducers of Differentiation or Apoptosis of Transformed Cells
Marks, P. A., Richon, V. M., & Rifkind, R. A. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.15.1210 · Cited by 1,157
Nucifora, F. C., Sasaki, M., Peters, M. F., Huang, H., Cooper, J. K., Yamada, M., Takahashi, H., Tsuji, S., Troncoso, J., Dawson, V. L., et al. (2001) · Science · doi:10.1126/science.1056784 · Cited by 1,094
Steffan, J. S., Kazantsev, A., Spasic-Boskovic, O., Greenwald, M., Zhu, Y.-Z., Gohler, H., Wanker, E. E., Bates, G. P., Housman, D. E., & Thompson, L. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.100110097 · Cited by 1,062 · cited 1×
“We previously found that a fragment of mutant Htt interacts directly with CBP, which contains an acetyltransferase domain and is a co-activator of numerous promoter”
BackgroundSelf-citationLuo, L., Liao, Y. J., Jan, L. Y., & Jan, Y. N. (1994) · Genes & Development · doi:10.1101/gad.8.15.1787 · Cited by 983
Cited by
Ravikumar, B., Vacher, C., Berger, Z., Davies, J. E., Luo, S., Oroz, L. G., Scaravilli, F., Easton, D. F., Duden, R., O'Kane, C. J., et al. (2004) · Nature Genetics · doi:10.1038/ng1362 · Cited by 2,347
Function and regulation of CREB family transcription factors in the nervous system
Lonze, B. E., & Ginty, D. D. (2002) · Neuron · doi:10.1016/s0896-6273(02)00828-0 · Cited by 2,127
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Huntington's disease: from molecular pathogenesis to clinical treatment
Ross, C. A., & Tabrizi, S. J. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70245-3 · Cited by 1,743
Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders
Falkenberg, K. J., & Johnstone, R. W. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4360 · Cited by 1,564
Trinucleotide Repeat Disorders
Orr, H. T., & Zoghbi, H. Y. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.29.051605.113042 · Cited by 1,368
UNRAVELING THE MECHANISMS INVOLVED IN MOTOR NEURON DEGENERATION IN ALS
Bruijn, L. I., Miller, T. M., & Cleveland, D. W. (2004) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.27.070203.144244 · Cited by 1,185
Toxic Proteins in Neurodegenerative Disease
Taylor, J. P., Hardy, J., & Fischbeck, K. H. (2002) · Science · doi:10.1126/science.1067122 · Cited by 1,251
Histone modifications in transcriptional regulation
Berger, S. L. (2002) · Current Opinion in Genetics & Development · doi:10.1016/s0959-437x(02)00279-4 · Cited by 1,220
Pandey, U. B., & Nichols, C. D. (2011) · Pharmacological Reviews · doi:10.1124/pr.110.003293 · Cited by 1,136
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines
Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T. (2002) · Nature Neuroscience · doi:10.1038/nn884 · Cited by 1,030
Huntingtin interacts with REST/NRSF to modulate the transcription of NRSE-controlled neuronal genes
Zuccato, C., Tartari, M., Crotti, A., Goffredo, D., Valenza, M., Conti, L., Cataudella, T., Leavitt, B. R., Hayden, M. R., Timmusk, T., et al. (2003) · Nature Genetics · doi:10.1038/ng1219 · Cited by 979
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
“Reduction in CBP-mediated HAT activity, when mutant huntingtin is expressed, was first described by Joan Steffan and Leslie Thompson and colleagues at the University of California Irvine in 2001 (550) (Fig.”
BackgroundInfluentialHockly, E., Richon, V. M., Woodman, B., Smith, D. L., Zhou, X., Rosa, E., Sathasivam, K., Ghazi-Noori, S., Mahal, A., Lowden, P. A. S., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0437870100 · Cited by 845
Self-citationVecsey, C. G., Hawk, J. D., Lattal, K. M., Stein, J. M., Fabian, S. A., Attner, M. A., Cabrera, S. M., McDonough, C. B., Brindle, P. K., Abel, T., et al. (2007) · Journal of Neuroscience · doi:10.1523/jneurosci.0296-07.2007 · Cited by 831
Novel targets for Huntington's disease in an mTOR-independent autophagy pathway
Williams, A., Sarkar, S., Cuddon, P., Ttofi, E. K., Saiki, S., Siddiqi, F. H., Jahreiss, L., Fleming, A., Pask, D., Goldsmith, P., et al. (2008) · Nature Chemical Biology · doi:10.1038/nchembio.79 · Cited by 800
Diseases of Unstable Repeat Expansion: Mechanisms and Common Principles
Gatchel, J. R., & Zoghbi, H. Y. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1691 · Cited by 794
Lim, J., Hao, T., Shaw, C., Patel, A. J., Szabó, G., Rual, J.-F., Fisk, C. J., Li, N., Smolyar, A., Hill, D. E., et al. (2006) · Cell · doi:10.1016/j.cell.2006.03.032 · Cited by 789
“…in understanding the normal function of the disease-causing protein and are beginning to identify pathways that could be targeted therapeutically (Steffan et al., 2001; Yoshida et al., 2002; Chen et al., 2003; Goehler et al., 2004; Ravikumar et al., 2004; Kaytor et al., 2005; Tsuda et al.,…”
BackgroundChromatin Remodeling Is a Key Mechanism Underlying Cocaine-Induced Plasticity in Striatum
Kumar, A., Choi, K.-H., Renthal, W., Tsankova, N. M., Theobald, D. E. H., Truong, H.-T., Russo, S. J., LaPlant, Q., Sasaki, T. S., Whistler, K. N., et al. (2005) · Neuron · doi:10.1016/j.neuron.2005.09.023 · Cited by 764
Molecular pathways to neurodegeneration
Bossy-Wetzel, E., Schwarzenbacher, R., & Lipton, S. A. (2004) · Nature Medicine · doi:10.1038/nm1067 · Cited by 740
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Kazantsev, A. G., & Thompson, L. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2681 · Cited by 711
Self-citationSUMO Modification of Huntingtin and Huntington's Disease Pathology
Steffan, J. S., Agrawal, N., Pallos, J., Rockabrand, E., Trotman, L. C., Slepko, N., Illes, K., Lukacsovich, T., Zhu, Y.-Z., Cattaneo, E., et al. (2004) · Science · doi:10.1126/science.1092194 · Cited by 713
Self-citationSp1 and TAFII130 Transcriptional Activity Disrupted in Early Huntington's Disease
Dunah, A. W., Jeong, H., Griffin, A., Kim, Y.-M., Standaert, D. G., Hersch, S. M., Mouradian, M. M., Young, A. B., Tanese, N., & Krainc, D. (2002) · Science · doi:10.1126/science.1072613 · Cited by 708
Ferrante, R. J., Kubilus, J. K., Lee, J., Ryu, H., Beesen, A., Zucker, B., Smith, K., Kowall, N. W., Ratan, R. R., Luthi-Carter, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-28-09418.2003 · Cited by 693
“…binding of the mutant huntingtin protein or cleaved products to a number of transcription factors, disrupting the normal pattern of gene transcription and resulting in functional and degenerative changes (Cha, 2000; McCampbell et al., 2000; Steffan et al., 2000, 2001; Sugars and Rubinsztein, 2003).”
InfluentialMultiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
“It is well known that the genetic mutation responsible for HD is an expansion of a CAG trinucleotide repeat encoding polyglutamine (polyQ) in the first exon of the huntingtin (HTT) gene.”
BackgroundInfluentialGunawardena, S., Her, L.-S., Brusch, R. G., Laymon, R. A., Niesman, I. R., Gordesky-Gold, B., Sintasath, L., Bonini, N. M., & Goldstein, L. S. B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00594-4 · Cited by 646
“For example, induced cytoplasmic accumulations and these accumuin mouse models, both loss (Dragatsis et al., 2000) and lations may promote abnormal protein-protein intergain of function of htt causes neurodegeneration (Man- actions that could trigger a cascade of toxic events, giarini et al., 1996; Difiglia et al., 19…”
Drosophila, the golden bug, emerges as a tool for human genetics
Bier, E. (2005) · Nature Reviews Genetics · doi:10.1038/nrg1503 · Cited by 625
14-3-3 proteins in the nervous system
Berg, D., Holzmann, C., & Riess, O. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1197 · Cited by 616
Epigenetic mechanisms in neurological diseases: genes, syndromes, and therapies
Urdinguio, R. G., Sanchez-Mut, J. V., & Esteller, M. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70262-5 · Cited by 582
Role of brain-derived neurotrophic factor in Huntington's disease
ZUCCATO, C., & CATTANEO, E. (2007) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2007.01.003 · Cited by 552
“They also found that a reduction in the acetyltransferase activity of CBP causes a reduction in histone acetylation (Steffan et al., 2001), thus leading to a more compact chromatin structure that is less accessible to transcription factors, and potentially explaining the decrease in CRE-dependent…”
BackgroundInfluentialHuntingtin–protein interactions and the pathogenesis of Huntington's disease
Li, S.-H., & Li, X.-J. (2004) · Trends in Genetics · doi:10.1016/j.tig.2004.01.008 · Cited by 548
α-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity
Kontopoulos, E., Parvin, J. D., & Feany, M. B. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl243 · Cited by 537
Transcriptional abnormalities in Huntington disease
Sugars, K. L., & Rubinsztein, D. C. (2003) · Trends in Genetics · doi:10.1016/s0168-9525(03)00074-x · Cited by 529
Choo, Y. S. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh162 · Cited by 515
The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases
Yang, X.-J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh252 · Cited by 515
Humbert, S., Bryson, E. A., Cordelières, F. P., Connors, N. C., Datta, S. R., Finkbeiner, S., Greenberg, M. E., & Saudou, F. (2002) · Developmental Cell · doi:10.1016/s1534-5807(02)00188-0 · Cited by 509
Huntington’s Disease: Mechanisms of Pathogenesis and Therapeutic Strategies
Jimenez-Sanchez, M., Licitra, F., Underwood, B. R., & Rubinsztein, D. C. (2017) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a024240 · Cited by 507
“Likewise, histone deacetylase (HDAC) inhibitors prevent neurodegeneration in cells, Drosophila or mouse models of HD (Steffan et al. 2001)(McCampbell et al. 2001)(Hockly et al. 2003)(Ferrante et al. 2003).”
CBP and p300: HATs for different occasions
Kalkhoven, E. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.03.045 · Cited by 496
Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders
ABEL, T., & ZUKIN, R. (2008) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.12.002 · Cited by 494
Katsuno, M., Adachi, H., Kume, A., Li, M., Nakagomi, Y., Niwa, H., Sang, C., Kobayashi, Y., Doyu, M., & Sobue, G. (2002) · Neuron · doi:10.1016/s0896-6273(02)00834-6 · Cited by 480
Gardian, G., Browne, S. E., Choi, D.-K., Klivenyi, P., Gregorio, J., Kubilus, J. K., Ryu, H., Langley, B., Ratan, R. R., Ferrante, R. J., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m410210200 · Cited by 456
Epigenetic mechanisms in neurological disease
Jakovcevski, M., & Akbarian, S. (2012) · Nature Medicine · doi:10.1038/nm.2828 · Cited by 450
HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis
Saha, R. N., & Pahan, K. (2006) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4401769 · Cited by 441
Filimonenko, M., Isakson, P., Finley, K. D., Anderson, M., Jeong, H., Melia, T. J., Bartlett, B. J., Myers, K. M., Birkeland, H. C. G., Lamark, T., et al. (2010) · Molecular Cell · doi:10.1016/j.molcel.2010.04.007 · Cited by 437
“This model has successfully identified genetic modifiers of polyglutamine toxicity (Bilen and Bonini, 2005; Kazemi-Esfarjani and Benzer, 2000; Lam et al., 2006; Pandey et al., 2007; Steffan et al., 2001).”
Huntingtin Interacting Proteins Are Genetic Modifiers of Neurodegeneration
Kaltenbach, L. S., Romero, E., Becklin, R. R., Chettier, R., Bell, R., Phansalkar, A., Strand, A., Torcassi, C., Savage, J., Hurlburt, A., et al. (2007) · PLoS Genetics · doi:10.1371/journal.pgen.0030082 · Cited by 434
“In addition, some of these proteins localize to insoluble Httfragment-containing inclusions present in affected tissues [15,16].”
BackgroundNEURODEGENERATIVE DISEASES: New Concepts of Pathogenesis and Their Therapeutic Implications
Skovronsky, D. M., Lee, V. M.-Y., & Trojanowski, J. Q. (2006) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev.pathol.1.110304.100113 · Cited by 425
Drosophila as a Model for Human Neurodegenerative Disease
Bilen, J., & Bonini, N. M. (2005) · Annual Review of Genetics · doi:10.1146/annurev.genet.39.110304.095804 · Cited by 422
Acetylation Targets Mutant Huntingtin to Autophagosomes for Degradation
Jeong, H., Then, F., Melia, T. J., Mazzulli, J. R., Cui, L., Savas, J. N., Voisine, C., Paganetti, P., Tanese, N., Hart, A. C., et al. (2009) · Cell · doi:10.1016/j.cell.2009.03.018 · Cited by 419
“Consistent with a previous finding that the glutamine-rich domain of CBP (CBPDQ) is not required for the CBP/Htt interaction (Steffan et al., 2001), CBPDQ also efficiently acetylated mutant Htt (Figure 1C).”
Genome-wide expression profiling of human blood reveals biomarkers for Huntington's disease
Borovecki, F., Lovrecic, L., Zhou, J., Jeong, H., Then, F., Rosas, H. D., Hersch, S. M., Hogarth, P., Bouzou, B., Jensen, R. V., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504921102 · Cited by 414
Huntington's disease: from pathology and genetics to potential therapies
Imarisio, S., Carmichael, J., Korolchuk, V., Chen, C.-W., Saiki, S., Rose, C., Krishna, G., Davies, J. E., Ttofi, E., Underwood, B. R., et al. (2008) · Biochemical Journal · doi:10.1042/bj20071619 · Cited by 409
Evidence for an epigenetic mechanism by which Hsp90 acts as a capacitor for morphological evolution
Sollars, V., Lu, X., Xiao, L., Wang, X., Garfinkel, M. D., & Ruden, D. M. (2003) · Nature Genetics · doi:10.1038/ng1067 · Cited by 409
Green, K. N., Steffan, J. S., Martinez-Coria, H., Sun, X., Schreiber, S. S., Thompson, L. M., & LaFerla, F. M. (2008) · The Journal of Neuroscience · doi:10.1523/jneurosci.3203-08.2008 · Cited by 404
“…in transgenic Drosophila and improve motor impairment and neuropathology in transgenic mouse models of both Huntington’s disease (HD) and spinal bulbar muscular atrophy (McCampbell et al., 2001; Steffan et al., 2001; Ferrante et al., 2003; Hockly et al., 2003; Minamiyama et al., 2004).”
BackgroundSelf-citationNitric oxide-induced nuclear GAPDH activates p300/CBP and mediates apoptosis
Sen, N., Hara, M. R., Kornberg, M. D., Cascio, M. B., Bae, B.-I., Shahani, N., Thomas, B., Dawson, T. M., Dawson, V. L., Snyder, S. H., et al. (2008) · Nature Cell Biology · doi:10.1038/ncb1747 · Cited by 407
Transcriptional dysregulation in Huntington’s disease
Cha, J.-H. J. (2000) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)01609-x · Cited by 397
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome
Thompson, L. M., Aiken, C. T., Kaltenbach, L. S., Agrawal, N., Illes, K., Khoshnan, A., Martinez-Vincente, M., Arrasate, M., O'Rourke, J. G., Khashwji, H., et al. (2009) · Journal of Cell Biology · doi:10.1083/jcb.200909067 · Cited by 396
“…the context of a large 350-kD protein; however, expressing just the N-terminal fragment of Htt encoded by exon 1 (Httex1p), which contains a highly expanded polyQ repeat, can precipitate an aggressive HD-like disease in transgenic mice and flies (Mangiarini et al., 1996; Steffan et al., 2001).”
BackgroundInfluentialSelf-citationEpigenetic Regulation in Neurodegenerative Diseases
Berson, A., Nativio, R., Berger, S. L., & Bonini, N. M. (2018) · Trends in Neurosciences · doi:10.1016/j.tins.2018.05.005 · Cited by 387
The epigenetics of aging and neurodegeneration
Lardenoije, R., Iatrou, A., Kenis, G., Kompotis, K., Steinbusch, H. W. M., Mastroeni, D., Coleman, P., Lemere, C. A., Hof, P. R., van den Hove, D. L. A., et al. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.05.002 · Cited by 381
“the application of HDACIs, showing promising results, both in terms of neuropathology and motor symptoms (Ferrante et al., 2004; Gardian et al., 2005; Igarashi et al., 2003; McFarland et al., 2012; Sadri-Vakili et al., 2007; Steffan et al., 2001; Sugai et al., 2004; Thomas et al., 2008).”
BackgroundProtein aggregates in Huntington's disease
Arrasate, M., & Finkbeiner, S. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.12.013 · Cited by 383
“CREB binding protein (CBP), a histone acetyltransferase, which also interacts with mutant Htt (Steffan et al., 2001), and HDAC1, a histone deacetylase, strongly increase and decrease acetylation of lysine 444, respectively.”
BackgroundEpigenetic regulation of gene expression in physiological and pathological brain processes
Gräff, J., Kim, D., Dobbin, M. M., & Tsai, L.-H. (2011) · Physiological Reviews · doi:10.1152/physrev.00012.2010 · Cited by 373
“Further supporting the notion of HD as a disease of aberrantly reduced histone acetylation, treatment with various HDAC inhibitors has been shown to rescue histone acetylation levels and to improve neurodegeneration and pathological symptoms in cellular, Drosophila, and mouse models (88, 104, 135, 296, 322, 337) (Tabl…”
BackgroundAggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells
Yang, W. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.23.2905 · Cited by 371
“The importance of the poly(Q) sequence for cytotoxicity, relative to other sequence elements in expanded CAG-repeat disease proteins, is also not always clear ( 24 ).”
BackgroundHuntington's disease: underlying molecular mechanisms and emerging concepts
Labbadia, J., & Morimoto, R. I. (2013) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2013.05.003 · Cited by 369
Luthi-Carter, R. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.17.1911 · Cited by 367
Watase, K., Weeber, E. J., Xu, B., Antalffy, B., Yuva-Paylor, L., Hashimoto, K., Kano, M., Atkinson, R., Sun, Y., Armstrong, D. L., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00733-x · Cited by 359
Choosing an animal model for the study of Huntington's disease
Pouladi, M. A., Morton, A. J., & Hayden, M. R. (2013) · Nature Reviews Neuroscience · doi:10.1038/nrn3570 · Cited by 356
Regulation of histone deacetylase activities
Sengupta, N., & Seto, E. (2004) · Journal of Cellular Biochemistry · doi:10.1002/jcb.20179 · Cited by 346
“Additionally, drugs that target HDACs potentially may be useful against malaria and toxoplasmosis, and for treatment of Huntington’s disease [Darkin-Rattray et al., 1996; Steffan et al., 2001].”
BackgroundLee, W.-C. M., Yoshihara, M., & Littleton, J. T. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400243101 · Cited by 343
The Role of Histone Acetylation in Memory Formation and Cognitive Impairments
Peixoto, L., & Abel, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.86 · Cited by 338
“The expansion has been shown to bind and inhibit the activity of the HAT domain of CBP and PCAF (Steffan et al, 2001).”
BackgroundInfluentialESCRTs and Fab1 Regulate Distinct Steps of Autophagy
Rusten, T. E., Vaccari, T., Lindmo, K., Rodahl, L. M. W., Nezis, I. P., Sem-Jacobsen, C., Wendler, F., Vincent, J.-P., Brech, A., Bilder, D., et al. (2007) · Current Biology · doi:10.1016/j.cub.2007.09.032 · Cited by 338
“in the ommatidia of the compound eye and was performed essentially as described earlier [46], with the following modifications: Decapitated heads were glued to drops of 1% agarose on a microscope slide with transparent nail varnish.”
MethodSIRT2 inhibition achieves neuroprotection by decreasing sterol biosynthesis
Luthi-Carter, R., Taylor, D. M., Pallos, J., Lambert, E., Amore, A., Parker, A., Moffitt, H., Smith, D. L., Runne, H., Gokce, O., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1002924107 · Cited by 336
Self-citationGiorgini, F., Guidetti, P., Nguyen, Q., Bennett, S. C., & Muchowski, P. J. (2005) · Nature Genetics · doi:10.1038/ng1542 · Cited by 328
Kuhn, A., Goldstein, D. R., Hodges, A., Strand, A. D., Sengstag, T., Kooperberg, C., Becanovic, K., Pouladi, M. A., Sathasivam, K., Cha, J.-H. J., et al. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm133 · Cited by 328
“The polyglutaminelength-dependent inhibition of histone acetylation has also been observed, and the reversal of histone acetylation deficits by the administration of histone deacetylase inhibitors improves the abnormal phenotype in yeast, Drosophila, cell and mouse models of polyglutamine disease (2,3, 43 ,44).”
BackgroundESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease
Ryu, H., Lee, J., Hagerty, S. W., Soh, B. Y., McAlpin, S. E., Cormier, K. A., Smith, K. M., & Ferrante, R. J. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0606373103 · Cited by 325
Histone deacetylation in epigenetics: An attractive target for anticancer therapy
Mai, A., Massa, S., Rotili, D., Cerbara, I., Valente, S., Pezzi, R., Simeoni, S., & Ragno, R. (2005) · Medicinal Research Reviews · doi:10.1002/med.20024 · Cited by 319
“Furthermore, HDACs and their inhibitors are involved in mental retardation(151) and neurodegeneration in Drosophila, respectively.(152)”
BackgroundDrosophila as an In Vivo Model for Human Neurodegenerative Disease
McGurk, L., Berson, A., & Bonini, N. M. (2015) · Genetics · doi:10.1534/genetics.115.179457 · Cited by 318
“This showed that HDAC inhibitors had the ability to mitigate the degenerative disease by protecting against retinal deterioration, providing the first evidence of HDAC inhibitors as a potential treatment option (Figure 4) (Steffan et al. 2001).”
BackgroundBiological roles and mechanistic actions of co-repressor complexes
Jepsen, K., & Rosenfeld, M. G. (2002) · Journal of Cell Science · doi:10.1242/jcs.115.4.689 · Cited by 317
Shukla, S., & Tekwani, B. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00537 · Cited by 314
The role of CREB signaling in Alzheimer’s disease and other cognitive disorders
Saura, C. A., & Valero, J. (2011) · revneuro · doi:10.1515/rns.2011.018 · Cited by 312
Epigenetic codes in cognition and behaviour
Gräff, J., & Mansuy, I. M. (2008) · Behavioural Brain Research · doi:10.1016/j.bbr.2008.01.021 · Cited by 309
“[84] Steffan JS, Bodai L, Pallos J, Poelman M, McCampbell A, Apostol BL,”
BackgroundInfluentialPolyglutamine Repeats in Neurodegenerative Diseases
Lieberman, A. P., Shakkottai, V. G., & Albin, R. L. (2019) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathmechdis-012418-012857 · Cited by 304
“Attempts to compensate for the diminished function of these and related factors using histone deacetylase (HDAC) inhibitors abrogated disease phenotypes in models of SBMA and HD (82, 83); subsequent work in models of other polyQ disorders showed similar beneficial effects.”
BackgroundCritical loss of CBP/p300 histone acetylase activity by caspase‐6 during neurodegeneration
Rouaux, C., Jokic, N., Mbebi, C., Boutillier, S., Loeffler, J., & Boutillier, A. (2003) · The EMBO Journal · doi:10.1093/emboj/cdg615 · Cited by 302
Androgen-Dependent Neurodegeneration by Polyglutamine-Expanded Human Androgen Receptor in Drosophila
Takeyama, K.-I., Ito, S., Yamamoto, A., Tanimoto, H., Furutani, T., Kanuka, H., Miura, M., Tabata, T., & Kato, S. (2002) · Neuron · doi:10.1016/s0896-6273(02)00875-9 · Cited by 301
Life extension in Drosophila by feeding a drug
Kang, H.-L., Benzer, S., & Min, K.-T. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.022631999 · Cited by 295
Thomas, E. A., Coppola, G., Desplats, P. A., Tang, B., Soragni, E., Burnett, R., Gao, F., Fitzgerald, K. M., Borok, J. F., Herman, D., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804249105 · Cited by 291
Aggregate formation inhibits proteasomal degradation of polyglutamine proteins
Verhoef, L. G. G. C. (2002) · Human Molecular Genetics · doi:10.1093/hmg/11.22.2689 · Cited by 292
“Among these are important regulators such as the CREB-binding protein (31) and the TATA-binding protein (42), which have been proposed as mediators of the neuronal toxicity observed in aggregate-containing cells ( 43 ).”
BackgroundKatsuno, M., Adachi, H., Doyu, M., Minamiyama, M., Sang, C., Kobayashi, Y., Inukai, A., & Sobue, G. (2003) · Nature Medicine · doi:10.1038/nm878 · Cited by 289
A model for studying Alzheimer's Aβ42-induced toxicity in Drosophila melanogaster
Finelli, A., Kelkar, A., Song, H.-J., Yang, H., & Konsolaki, M. (2004) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2004.03.001 · Cited by 287
Rockabrand, E., Slepko, N., Pantalone, A., Nukala, V. N., Kazantsev, A., Marsh, J. L., Sullivan, P. G., Steffan, J. S., Sensi, S. L., & Thompson, L. M. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddl440 · Cited by 286
Self-citationDeregulation of HDAC1 by p25/Cdk5 in Neurotoxicity
Kim, D., Frank, C. L., Dobbin, M. M., Tsunemoto, R. K., Tu, W., Peng, P. L., Guan, J.-S., Lee, B.-H., Moy, L. Y., Giusti, P., et al. (2008) · Neuron · doi:10.1016/j.neuron.2008.10.015 · Cited by 286
Polyglutamine diseases: emerging concepts in pathogenesis and therapy
Shao, J., & Diamond, M. I. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm213 · Cited by 287
Lessons from animal models of Huntington's disease
Rubinsztein, D. C. (2002) · Trends in Genetics · doi:10.1016/s0168-9525(01)02625-7 · Cited by 283
Delivery of peptide and protein drugs over the blood–brain barrier
Brasnjevic, I., Steinbusch, H. W. M., Schmitz, C., & Martinez-Martinez, P. (2009) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2008.12.002 · Cited by 279
Usdin, K. (2008) · Genome Research · doi:10.1101/gr.070409.107 · Cited by 269
“Histone deacetylase inhibitors alleviate polyQ toxicity in various model systems (Steffan et al. 2001; Hughes 2002; Hockly et al. 2003; Bates et al. 2006), consistent with the hypothesis that polyQ toxicity results from the sequestering of proteins that affect gene expression by altering normal…”
BackgroundWarrick, J. M., Morabito, L. M., Bilen, J., Gordesky-Gold, B., Faust, L. Z., Paulson, H. L., & Bonini, N. M. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.030 · Cited by 267
“Transcriptional dysfunction is widely viewed as a potential pathogenic mechanism underlying polyQ degeneration (Steffan et al., 2001; Zuccato et al., 2001).”
BackgroundPallos, J., Bodai, L., Lukacsovich, T., Purcell, J. M., Steffan, J. S., Thompson, L. M., & Marsh, J. L. (2008) · Human Molecular Genetics · doi:10.1093/hmg/ddn273 · Cited by 265
Self-citationPathogenesis of NUT Midline Carcinoma
French, C. A. (2012) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011811-132438 · Cited by 264
Huang, Y., Doherty, J. J., & Dingledine, R. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-19-08422.2002 · Cited by 259
“HDAC inhibitors reduce neurodegeneration in a mouse model of mild stroke (Endres et al., 2000) and in a Drosophila model of polyglutamine repeat disease (Steffan et al., 2001).”
The Kynurenine Pathway Modulates Neurodegeneration in a Drosophila Model of Huntington's Disease
Campesan, S., Green, E. W., Breda, C., Sathyasaikumar, K. V., Muchowski, P. J., Schwarcz, R., Kyriacou, C. P., & Giorgini, F. (2011) · Current Biology · doi:10.1016/j.cub.2011.04.028 · Cited by 258
Ryu, H., Lee, J., Olofsson, B. A., Mwidau, A., Deodoglu, A., Escudero, M., Flemington, E., Azizkhan-Clifford, J., Ferrante, R. J., & Ratan, R. R. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0737363100 · Cited by 261
Molecular pathogenesis of spinocerebellar ataxias
Duenas, A. M. (2006) · Brain · doi:10.1093/brain/awl081 · Cited by 260
Metadata
- Authors
- Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., Kurokawa, R., Housman, D. E., Jackson, G. R., Marsh, J. L., & Thompson, L. M.
- Affiliations
- University of California, Irvine (US)
- National Institutes of Health (US)
- Massachusetts Institute of Technology (US)
- University of California San Diego (US)
- University of California, Los Angeles (US)
- Corresponding author
- Thompson, Leslie M.
- ORCID
- Venue
- Nature
- Published
- 2001-10
- Volume
- 413
- Issue
- 6857
- Pages
- 739-743
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W1643390591
- Cited by
- 1,228
- References
- 28
- Citations by year
- 2026: 12 · 2025: 15 · 2024: 26 · 2023: 21 · 2022: 31 · 2021: 35 · 2020: 35 · 2019: 30 · 2018: 37 · 2017: 34 · 2016: 40 · 2015: 46 · 2014: 63 · 2013: 65 · 2012: 55
- FWCI
- 26.66
- Type
- journal article
- Language
- en
- Open access
- green
- escholarship.org
- Licence
- cc-by
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion, cc-by)
- Funders
- Hereditary Disease Foundation
- National Institutes of Health
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetics and Neurodevelopmental Disorders
- Keywords
- histone deacetylase inhibitors, polyglutamine expansion, Huntington's disease, neurodegeneration, huntingtin exon 1, CREB-binding protein, P300, PCAF, histone acetylation, histone deacetylase, Drosophila model, transcriptional dysregulation
- MeSH terms
- Huntingtin Protein, Acetylation, Acetyltransferases, Animals, Disease Models, Animal, Drosophila, Enzyme Inhibitors, Gene Expression Regulation, Glutamine, Glutathione Transferase, Histone Deacetylases, Histones, Huntington Disease, Nerve Degeneration, Nerve Tissue Proteins, Nuclear Proteins, Peptides, Repressor Proteins, Trans-Activators, PC12 Cells, Protein Structure, Tertiary, Neurodegenerative Diseases, Repetitive Sequences, Amino Acid, Saccharomyces cerevisiae Proteins, Drosophila Proteins, Animals, Genetically Modified, E1A-Associated p300 Protein, CREB-Binding Protein, Rats, Histone Acetyltransferases, Sin3 Histone Deacetylase and Corepressor Complex, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.